Drug Designing through Genetically Engineered Plants


  • Prof. Ch. Hara Prasad Mishra, Prof. Prafulla Kumar Das


In recent years, genetically modified (or GM) plants have been and continued to receive a significant number of media attention. Nevertheless, the public is largely unaware of the real nature or the pros and cons of a GM plant, particularly as concerning the range of applications to be used. Two key areas of concern appeared from the first generation of GM crops, namely environmental and health risk. With the gradual introduction of GM plants into the European Union, public concern about potential health problems is likely to grow. While the 'health campaigns' are now common to the press, their published information is often unreliable and irrepressible to the scientific evidence available. In the production of new therapeutic agents from the botanical sources, modern biotechnology has regenerated the interest. With nearly 500 biopharmaceuticals licensed or produced globally and the processing capability are limited, the requirement for efficient methods of pharmaceutical protein synthesis is evident. Plants are also available to produce "mammalian anti-corps, blood substance equivalents, vaccinations, hormones, cytokines as well as other medicinal agents," which are biologically active proteins by genetic modification methods. A correct host plants and cell proliferation system collection, such as a determination whether a nutrition plant or even a non - edible crop is much more suitable, is involved in an effective biopharmaceutical production for the plants.




How to Cite

Prof. Ch. Hara Prasad Mishra, Prof. Prafulla Kumar Das. (2020). Drug Designing through Genetically Engineered Plants. International Journal of Modern Agriculture, 9(3), 617 - 623. Retrieved from http://www.modern-journals.com/index.php/ijma/article/view/259